425: Graphite Bio Addresses Litigation and Provides Supplemental Disclosures Regarding Lenz Therapeutics Merger

Graphite Bio provides supplemental disclosures related to its proposed merger with Lenz Therapeutics in response to stockholder complaints and demand letters alleging misrepresentations and omissions in the preliminary proxy statement/prospectus.

Summary

• Graphite Bio is addressing litigation and demand letters related to its proposed merger with Lenz Therapeutics.
• The complaints allege misrepresentations and omissions in the proxy statement/prospectus filed with the SEC.
• The allegations concern Lenz's financial projections, the financial advisor's analyses, potential conflicts of interest, and Graphite's liquidation analysis.
• Graphite denies the allegations but is providing supplemental disclosures to avoid nuisance, expense, and delays.
• The supplemental disclosures relate to the background of the transaction, the Graphite liquidation analysis, Leerink Partners' discounted cash flow analysis and general information, and non-employee director compensation.
• The company intends to vigorously defend against the complaints and demands.
• The company is providing additional information to its stockholders.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is facing litigation, it is taking proactive steps to address the concerns and move forward with the merger. The supplemental disclosures provide additional transparency, but the legal challenges introduce uncertainty.

Positives

• Graphite Bio is proactively addressing concerns raised by stockholders regarding the proposed merger.
• The company is providing additional transparency through supplemental disclosures.
• Graphite intends to vigorously defend against the complaints and demands, suggesting confidence in its position.

Negatives

• Litigation and demand letters have been filed, alleging misrepresentations and omissions in the proxy statement/prospectus.
• The merger is facing potential legal challenges, which could delay or prevent its completion.
• The supplemental disclosures indicate that there were concerns raised about the fairness and accuracy of the initial disclosures.

Risks

• The outcome of the litigation and demand letters is uncertain.
• Additional lawsuits may be filed or demand letters received.
• The merger could be delayed or blocked by court order.
• The market price of Graphite's common stock could be affected by the litigation and the merger.
• The combined company may not achieve the anticipated benefits of the merger.
• The private financing may not be consummated upon the Closing.

Future Outlook

The document contains forward-looking statements regarding the merger with Lenz Therapeutics, the combined company's listing on Nasdaq, the timing of the merger, the expected executive officers and directors, the cash position and runway of the combined company, future operations, commercialization activities, clinical drug development activities, and related timelines.

Management Comments

• Graphite believes that the disclosures set forth in the Proxy Statement/Prospectus comply fully with all applicable laws.
• Graphite specifically denies all allegations in the Complaints and the Demands that any additional disclosure was or is required or is material.

Industry Context

The announcement reflects the increasing scrutiny of mergers and acquisitions, with stockholders actively challenging disclosures and seeking additional information. This trend highlights the importance of transparency and thoroughness in M&A transactions.

Comparison to Industry Standards

• It is common for companies undergoing mergers to face litigation from stockholders alleging inadequate disclosures.
• The supplemental disclosures provided by Graphite are similar to those often provided by companies in response to such litigation to avoid delays and expenses.
• The liquidation analysis and discounted cash flow analysis are standard valuation methods used in M&A transactions, and the details provided are consistent with industry practices.

Legal Proceedings

• One complaint has been filed in the United States District Court for the Northern District of California captioned Glen Chew v. Graphite Bio, Inc. et al., Case No. 3:24-cv-00613 (filed February 1, 2024).
• One complaint has been filed in the United States District Court for the District of Delaware captioned Kevin Turner v. Graphite Bio, Inc. et al., Case No. 1:24-cv-00241-UNA (filed February 22, 2024).
• Graphite has also received twelve additional demand letters by purported Graphite stockholders from December 14, 2023 to February 28, 2024 seeking additional disclosures in the Proxy Statement/Prospectus (the Demands).

Stakeholder Impact

• Shareholders: The merger and related litigation could impact the value of their shares.
• Employees: The merger could result in changes to their roles and responsibilities.
• Customers: The merger could impact the availability and development of new products.
• Suppliers: The merger could impact their relationships with the combined company.
• Creditors: The merger could impact the creditworthiness of the combined company.

Next Steps

• Graphite will continue to defend against the Complaints and the Demands.
• Graphite will seek stockholder approval for the merger.
• Graphite will work to satisfy the conditions to the closing of the merger.
• The combined company will focus on commercialization activities and clinical drug development.

Key Dates